Analysis of GB virus C infection among HIV-HCV coinfected patients

The aim of this study was to evaluate the effect of GB virus C on laboratory markers and histological parameters among HIV-seropositive patients coinfected with HCV. Lower degrees of hepatic lesions were observed in the triple-infected patients, in comparison with HIV-HCV coinfected patients who were negative for GBV-C RNA.

Evaluation of the therapeutic response of hepatitis C in coinfected patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon

INTRODUCTION: The aim of this study was to evaluate the therapeutic response of hepatitis C in patients coinfected with human immunodeficiency virus (HIV-1). METHODS: A retrospective study of 20 patients coinfected with HIV-1/HCV who were treated in the outpatient liver clinic at the Sacred House of Mercy Foundation Hospital of Pará (Fundação Santa Casa de Misericórdia do Pará - FSCMPA) from April 2004 to June 2009. Patients were treated with 180µg PEG interferon-α2a in combination with ribavirin (1,000 to 1,250mg/day) for 48 weeks. The end point was the sustained virological response (SVR) rate (HCV RNA negative 24 weeks after completing treatment). RESULTS: The mean age of the patients was 40±9.5 years, of which 89% (n=17) were male, and the HCV genotypes were genotype 1 (55%, n=11/20), genotype 2 (10%, n=2/20) and genotype 3 (35%, n=7/20). The mean CD4+ lymphocyte count was 507.8, and the liver fibrosis stages were (METAVIR) F1 (25%), F2 (55%), F3 (10%) and F4 (10%). The early virological response (EVR) was 60%, the end-of-treatment virological response (EOTVR) was 45% and the SVR was 45%. CONCLUSIONS: The median HCV viral load was high, and in 85% of cases in which highly active antiretroviral therapy (HAART) was used, none of the patients with F3-F4 fibrosis responded to treatment. Of the twenty patients treated, 45% achieved SVR and 45% achieved EOTVR. Studies that include cases from a wider region are needed to better evaluate these findings.

Mineralogia e geoquímica de perfis de solo com Terra Preta Arqueológica de Bom Jesus do Tocantins, sudeste da Amazônia

A comparação de dados morfológicos, mineralógicos e químicos de solo com horizontes antrópicos - Terra Preta Arqueológica (TPA) com Argissolos adjacentes permitiu identificar os principais processos responsáveis pela formação da TPA em um sítio arqueológico no Município de Bom Jesus do Tocantins, sudeste do Estado do Pará. A similaridade entre os dados dos horizontes subsuperficiais do solo com TPA e solos adjacentes indica que o horizonte antrópico do solo TPA foi provavelmente desenvolvido a partir de um horizonte similar aos Argissolos adjacentes com posterior transformação pedogenética através da introdução de materiais orgânicos e inorgânicos por antigas colonizações humanas, resultando no espessamento do horizonte superficial e em concentrações maiores de CaO e P2O5 (teores totais), Zn (teor traço), P e Zn disponível (teores disponíveis), além de Ca e Mg trocáveis (teores trocáveis) em relação aos Argissolos adjacentes. Além disso, essa intervenção antrópica antiga também provocou modificações no horizonte subsuperficial do Argissolo com TPA, como concentrações altas de P2O5 e principalmente P disponível. O Soil Taxonomy e o Sistema Brasileiro de Classificação de Solos (SiBCS) são adequados para a identificação de solo com horizonte antrópico (p.exe. TPA), uma vez que priorizam nas ordens do solo os principais processos pedogenéticos atuantes na formação do solo, relacionados aos horizontes subsuperficiais, além das transformações pedogenéticas posteriores no horizonte superficial. Contudo, este trabalho recomenda o acréscimo de alguns atributos diagnósticos como quantidade de artefatos cerâmicos e líticos, P2O5, P e Zn disponíveis, C orgânico, Ca2++ Mg2+ (teores trocáveis), CTC e índice de saturação por bases no horizonte superficial para o agrupamento e distinção dos diversos tipos de solos antrópicos antigos da Amazônia.

Composição mineral e sintomas visuais de deficiências de nutrientes em plantas de pimenta-longa (Piper hispidinervum C. DC.)

A pimenta-longa (Piper hispidinervum C. DC.) é uma das principais fontes alternativas para a produção de safrol empregado como matéria prima na fabricação de inseticidas naturais e aromatizantes. O objetivo da pesquisa foi avaliar o efeito da omissão dos macronutrientes e micronutrientes, sobre a composição mineral de plantas de pimenta-longa, e caracterizar os sintomas de deficiências decorrentes dessa limitação, utilizando-se da técnica do elemento faltante. O experimento foi conduzido em casa de vegetação, com quatro repetições e doze tratamentos, completo e omissão individual de N, P, K, Ca, Mg, S, B, Cu, Fe, Mn e Zn em delineamento inteiramente ao acaso. Os valores dos teores foliares nos tratamentos com omissão dos nutrientes foram inferiores àqueles obtidos no tratamento completo. As omissões individuais dos nutrientes promoveram alterações na composição mineral de macro e micronutrientes. Os teores de macronutrientes (g kg-1) e micronutrientes (mg kg-1) obtidos nas folhas sem (completo) e com sintomas de deficiências (omissões) foram, respectivamente: N = 18,32; P = 7,02; K = 22,17; Ca = 15,75; Mg = 8,25; S = 5,12; B = 42,25; Fe = 325,00; Mn = 100; Zn = 61,50, com deficiência: N = 8,98; P = 2,52; K = 8,57; Ca = 10,20; Mg = 1,85; S = 0,90; B = 15,50; Fe = 234,00; Mn = 55; Zn = 53.

Japan, as represented in Field Museum of Natural History / by Helen C. Gunsaulus, Assistant Curator of Japanese Ethnology.

Fieldiana, Popular Series, Anthropology, no. 3, 11

Japanese collections : Frank W. Gunsaulus Hall / by Helen C. Gunsaulus, Assistant Curator of Japanese Ethnology

no.3(1922)

Hepatitis C Virus Infection and Kidney Transplantation in 2014: What's New?

Chronic hepatitis C virus (HCV) infection remains an important health problem, which is associated with deleterious consequences in kidney transplant recipients. Besides hepatic complications, several extrahepatic complications contribute to reduced patient and allograft survival in HCV-infected kidney recipients. However, HCV infection should not be considered as a contraindication for kidney transplantation because patient survival is better with transplantation than on dialysis. Treatment of HCV infection is currently interferon-alpha (IFN-α) based, which has been associated with higher renal allograft rejection rates. Therefore, antiviral treatment before transplantation is preferable. As in the nontransplant setting, IFN-free treatment regimens, because of their greater efficacy and reduced toxicity, currently represent promising and attractive therapeutic options after kidney transplantation as well. However, clinical trials will be required to closely evaluate these regimens in kidney recipients. There is also a need for prospective controlled studies to determine the optimal immunosuppressive regimens after transplantation in HCV-infected recipients. Combined kidney and liver transplantation is required in patients with advanced liver cirrhosis. However, in patients with cleared HCV infection and early cirrhosis without portal hypertension, kidney transplantation alone may be considered. There is some agreement about the use of HCV-positive donors in HCV-infected recipients, although data regarding posttransplant survival rates are controversial.

The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C.

Summary.  The outcome of hepatitis C virus (HCV) infection and the likelihood of a sustained virological response (SVR) to antiviral therapy depends on both viral and host characteristics. In vitro studies demonstrated that bile acids (BA) interfere with antiviral interferon effects. We investigate the influence of plasma BA concentrations and an ABCB11 polymorphism associated with lower transporter expression on viral load and SVR. Four hundred and fifty-one Caucasian HCV-patients treated with PEG-interferon and ribavirin were included in the study. ABCB11 1331T>C was genotyped, and plasma BA levels were determined. The 1331C allele was slightly overrepresented in HCV-patients compared to controls. In HCV-patients, a significant difference between patients achieving SVR vs non-SVR was observed for HCV-2/3 (5 vs 9 μm; P = 0.0001), while median BA levels in HCV-1 were marginally elevated. Normal BA levels <8 μm were significantly associated with SVR (58.3%vs 36.3%; OR 2.48; P = 0.0001). This difference was significant for HCV-2/3 (90.7%vs 67.6%; P = 0.002) but marginal in HCV-1 (38.7%vs 27.8%; P = 0.058). SVR rates were equivalent between ABCB11 genotypes for HCV-1, but increased for HCV-2/3 (TT 100%vs CC 78%; OR 2.01; P = 0.043). IL28B genotype had no influence on these associations. No correlation between BA levels and HCV RNA was detected for any HCV genotype. The higher allelic frequency of ABCB11 1331C in HCV-patients compared to controls may indirectly link increased BA to HCV chronicity. Our data support a role for BA as host factor affecting therapy response in HCV-2/3 patients, whereas a weaker association was found for HCV-1.

Influence of GB virus C on IFN-γ and IL-2 production and CD38 expression in T lymphocytes from chronically HIV-infected and HIV-HCV-co-infected patients

This study was designed to assess the effect of GB virus (GBV)-C on the immune response to human immunodeficiency virus (HIV) in chronically HIV-infected and HIV- hepatitis C virus (HCV)-co-infected patients undergoing antiretroviral therapy. A cohort of 159 HIV-seropositive patients, of whom 52 were HCV-co-infected, was included. Epidemiological data were collected and virological and immunological markers, including the production of interferon gamma (IFN-γ) and interleukin (IL)-2 by CD4, CD8 and Tγδ cells and the expression of the activation marker, CD38, were assessed. A total of 65 patients (40.8%) presented markers of GBV-C infection. The presence of GBV-C did not influence HIV and HCV replication or TCD4 and TCD8 cell counts. Immune responses, defined by IFN-γ and IL-2 production and CD38 expression did not differ among the groups. Our results suggest that neither GBV-C viremia nor the presence of E2 antibodies influence HIV and HCV viral replication or CD4 T cell counts in chronically infected patients. Furthermore, GBV-C did not influence cytokine production or CD38-driven immune activation among these patients. Although our results do not exclude a protective effect of GBV-C in early HIV disease, they demonstrate that this effect may not be present in chronically infected patients, who represent the majority of patients in outpatient clinics.

Périartérite noueuse et hépatite C: association fortuite [Periarteritis nodosa and hepatitis C: a fortuitous association?]

Polyarteritis nodosa is a vasculitis of unknown origin which can be rarely associated with hepatitis B. A exceptional clinical situation of a polyarteritis nodosa associated with hepatitis C is described. This case is also the occasion to review the clinical manifestations, the diagnostic strategy und the therapeutic options of this rare vasculitis.

Age above 60 years is not a negative predictive factor for combined antiviral therapy with pegylated interferon alpha and ribavirin in hepatitis C patients

Background: Age is frequently discussed as negative host factor to achieve a sustained virological response (SVR) to antiviral hepatitis C therapy. However, elderly patients often show relevant fibrosis or cirrhosis which is a known negative predictive factor, making it difficult to interpret age as an independent predictive factor. Methods: From the framework of the Swiss hepatitis C cohort (SCCS), we collected data from 545 antiviral hepatitis C therapies, including data from 67 hepatitis C patients ≥ 60 y who had been treated with PEG-interferon and ribavirin. We analyzed host factors (age, gender, fibrosis, haemoglobin, depression, earlier hepatitis C treatment), viral factors (genotype, viral load) and treatment course (early virological response, end of treatment response, SVR). Generalised estimating equations (GEE) regression modelling was used for the primary end point (SVR), with age ≥ 60 y and < 60 y as independent variable and gender, presence of cirrhosis, genotype, earlier treatment and viral load as confounders. SVR was analysed in young and elderly patients after matching for these confounders. Additionally, classification tree analysis was done in elderly patients using these confounders. Results: SVR analyzed in 545 patients was 55%. In genotype 1/4, SVR was 42.9% in 259 patients < 60 y and 26.1% in 46 patients ≥ 60 y. In genotype 2/3, SVR was 74.4% in 215 patients < 60 y and 84% in 25 patients ≥ 60 y. However, GEE model showed that age had no influence on achieving SVR (Odds ratio 0.91). Confounders influenced SVR as known from previous studies (cirrhosis, genotype 1/4, previous treatment and viral load >600'000 IE/ml as negative predictive factors). When young and elderly patients were matched (analysis in 59 elderly patients), SVR was not different in these patient groups (54.2% and 55.9%, resp.; p=0.795 in binomial test). The classification tree-derived best criterion for SVR in elderly patients was genotype, with no further criteria relevant for predicting SVR in genotype 2/3. In patients with genotype 1/4, further criteria were presence of cirrhosis and low viral load <600'000 IE/ml in non-cirrhotic patients. Conclusions: Age is not a relevant predictive factor for achieving SVR, when confounders were taken into account. In terms of effectiveness of antiviral therapy, age does not play a major role and should not be regarded as relevant negative predictive factor. Since life expectancy in Switzerland at age 60 is more than 22 y, hepatitis C therapy is reasonable in elderly patients with known relevant fibrosis or cirrhosis, because interferon-based hepatitis C therapy improves survival and reduces carcinogenesis.